Lee JB - Search Results

1

Neoadjuvant and adjuvant osimertinib in stage IA-IIIA, EGFR-mutant non-small cell lung cancer (NORA).

Lee JB, Choi SJ, Shim HS, Park BJ, Lee CY, Sudhaman S, Velichko S, Hong MH, Cho BC, Lim SM. Lee JB, et al. J Thorac Oncol. 2024 Dec 26:S1556-0864(24)02544-9. doi: 10.1016/j.jtho.2024.12.023. Online ahead of print. J Thorac Oncol. 2024. PMID: 39732365 Free article.

2

Lazertinib in pretreated EGFR T790M-mutated advanced non-small cell lung cancer: A real-world multicenter study.

Kim H, Ahn BC, Lee J, Lee JB, Hong MH, Kim HR, Cho BC, Lim SM. Kim H, et al. Among authors: lee jb, lee j. Lung Cancer. 2023 Jun;180:107213. doi: 10.1016/j.lungcan.2023.107213. Epub 2023 Apr 21. Lung Cancer. 2023. PMID: 37104879

3

Chemotherapy and Osimertinib Combination Should Not Be the First-Line Treatment for All Advanced EGFR+ NSCLC.

Lim SM, Lee JB, Cho BC. Lim SM, et al. Among authors: lee jb. J Thorac Oncol. 2024 Mar;19(3):376-379. doi: 10.1016/j.jtho.2023.12.007. J Thorac Oncol. 2024. PMID: 38453325 No abstract available.

4

Analysis of tumor mutational burden and mutational landscape comparing whole-exome sequencing and comprehensive genomic profiling in patients with resectable early-stage non-small-cell lung cancer.

Choi SJ, Lee JB, Kim JH, Hong MH, Cho BC, Lim SM. Choi SJ, et al. Among authors: lee jb. Ther Adv Med Oncol. 2024 Mar 21;16:17588359241240657. doi: 10.1177/17588359241240657. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 38523846 Free PMC article.

5

Real-World Outcomes with Lurbinectedin in Second Line and Beyond for Extensive Stage Small Cell Lung Cancer in Korea.

Shim JS, Kim Y, Yuh T, Lee JB, Kim HR, Hong MH, Cho BC, Lim SM. Shim JS, et al. Among authors: lee jb. Lung Cancer (Auckl). 2024 Oct 30;15:149-159. doi: 10.2147/LCTT.S485320. eCollection 2024. Lung Cancer (Auckl). 2024. PMID: 39494146 Free PMC article.

6

Overexpression of PVR and PD-L1 and its association with prognosis in surgically resected squamous cell lung carcinoma.

Lee JB, Hong MH, Park SY, Chae S, Hwang D, Ha SJ, Shim HS, Kim HR. Lee JB, et al. Sci Rep. 2021 Apr 20;11(1):8551. doi: 10.1038/s41598-021-87624-x. Sci Rep. 2021. PMID: 33879814 Free PMC article.

7

Patritumab Deruxtecan: Paving the Way for EGFR-TKI-Resistant NSCLC.

Lim SM, Kim CG, Lee JB, Cho BC. Lim SM, et al. Among authors: lee jb. Cancer Discov. 2022 Jan;12(1):16-19. doi: 10.1158/2159-8290.CD-21-1429. Cancer Discov. 2022. PMID: 35022206

8

Plasma tumor mutation burden is associated with clinical benefit in patients with non-small cell lung cancer treated with anti-programmed death-1 monotherapy.

Lee JB, Park HS, Choi SJ, Heo SG, An HJ, Kim HR, Hong MH, Lim SM, Chang K, Quinn K, Odegaard J, Shim BY, Cho BC. Lee JB, et al. Ther Adv Med Oncol. 2022 Dec 17;14:17588359221141761. doi: 10.1177/17588359221141761. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 36544541 Free PMC article.

9

Advances in the management of non-small-cell lung cancer harbouring EGFR exon 20 insertion mutations.

Low JL, Lim SM, Lee JB, Cho BC, Soo RA. Low JL, et al. Among authors: lee jb. Ther Adv Med Oncol. 2023 Jan 27;15:17588359221146131. doi: 10.1177/17588359221146131. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 36756143 Free PMC article. Review.

10

Clinical utility of a plasma-based comprehensive genomic profiling test in patients with non-small cell lung cancer in Korea.

Ahn BC, Lee S, Lee J, Lee JB, Hong MH, Lim SM, Jain S, Olsen S, Cho BC. Ahn BC, et al. Among authors: lee jb, lee j, lee s. Cancer Treat Res Commun. 2023;36:100715. doi: 10.1016/j.ctarc.2023.100715. Epub 2023 Jun 8. Cancer Treat Res Commun. 2023. PMID: 37307681 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,300 results

Search Page

Filters